Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists?

  • R. Markstein
  • J.-M. Vigouret
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


This overview summarises recent experimental findings suggesting that an optimal motor control in Parkinson’s disease depends on concurrent activation of D-1 and D-2 receptors. The clinical observation that a combination of bromocriptine (Parlodel; Pravidel) with L-DOPA produces better symptomatic control in Parkinson patients than either agent alone is explained as the result of a synergistic interaction between D-2 receptors activated by Parlodel and D-1 receptors activated by dopamine formed from L-DOPA.


Dopamine Receptor Dopamine Agonist Endogenous Dopamine Cerebral Glucose Utilisation Sensory Motor Cortex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amt J, Hyttel J (1986) Inhibition of SKF 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro. J Neural Transm 67: 225–240CrossRefGoogle Scholar
  2. Bokobza B, Ruberg M. Scatton B, Javoy-Agid F, Agid Y (1984) [3H]spiperone binding and HVA concentrations in Parkinson’s disease and supra-nuclear palsy. European J Pharmacol 99: 167–175CrossRefGoogle Scholar
  3. Bouchard S (1987) Optimum symptomatic control of Parkinson’s disease with dopaminergic therapy. Canad J Neurol Sci 14 [Suppl]: 460–465PubMedGoogle Scholar
  4. Braun AR, Chase TN (1986) Obligatory D-1 and D-2 receptor interaction in the generation of dopamine agonist related behaviors. European J Pharmacol 131: 301–306CrossRefGoogle Scholar
  5. Braun AR, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN (1987) Selective D-1 dopamine agonist treatment of Parkinson’s disease. J Neural Transm 68: 41–50PubMedCrossRefGoogle Scholar
  6. Burns RS, Phillips JM, Chiueh CC, Parisi JE (1986) The MPTP-treated monkey model of Parkinson’s disease. In: Markey SP, Castagnoli N, Trevor AJ, Kopin IJ (eds) MPTP: A neurotoxin producing a Parkinsonian syndrome. Academic Press, Orlando, pp 23–42Google Scholar
  7. Caine DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK (1974) Treatment of Parkinsonism with bromocriptine. Lancet ii: 1355–1356Google Scholar
  8. Chiodo LA, Bannon MJ, Grace AA, Roth RH, Bunney BS (1984) Evidence for the absence of impulse regulating somatodendritic and synthesis modulating nerve terminal autoreceptors on subpopulations of mesocortical neurons. Neuroscience 12: 1–16PubMedCrossRefGoogle Scholar
  9. Girault JA, Spampinato U, Glowinski J, Besson MJ (1986) In vivo release of [3H]gamma-aminobutyric acid in the rat neostriatum. II. Opposing effects of D-1 and D-2 dopamine receptor stimulation in the dorsal caudate putamen. Neuroscience 19: 1109–1117PubMedCrossRefGoogle Scholar
  10. Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellote WW (1986) Dopamine D-2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 19: 497–492CrossRefGoogle Scholar
  11. Jackson DM, Hashizume M (1986) Bromocriptine induces marked loco-motor stimulation in dopamine-depleted mice, when D-1 dopamine receptors are stimulated with SKF 38393. Psychopharmacology 90: 147–149PubMedGoogle Scholar
  12. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz 0 (1978): Receptor basis for dopaminergic supersensitivity in Parkinson’s disease. Nature 273: 59–61Google Scholar
  13. Markstein R, Seiler MP, Vigouret JM, Urwyler S, Enz A, Palacios JM, Wiederhold KH, Dixon K, Hofmann A, Wuetherich H (1988) CY 208–243, a novel D-1 receptor partial agonist. European J Pharmacol (in press)Google Scholar
  14. Mashurano M, Waddington JL (1986): Stereotyped behaviour in response to the selective D-2 receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SKF 38393. Neuropharmacology 25: 947–949PubMedCrossRefGoogle Scholar
  15. Molloy AG, Waddington JL (1984) Dopaminergic behaviour stereospecifically promoted by the D-1 agonist R-SK and F 38393 and selectively blocked by the D-1 antagonist SCH 23390. Psychopharmacology 82: 409–410PubMedCrossRefGoogle Scholar
  16. Moore NA, Axton MS (1988) Production of climbing behaviour in mice requires both D-1 and D-2 receptor activation. Psychopharmacology 94: 263–266PubMedCrossRefGoogle Scholar
  17. Nomoto M, Jenner P, Marsden CD (1985) The dopamine D-2 agonist LY 141865, but not the D-1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( MPTP) in the common marmoset, Neurosci Lett 57: 37–41Google Scholar
  18. Raisman R, Cash R, Ruberg M, Javoy-Agid F, Agid Y (1985) Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. European J Pharmacol 123: 467–468CrossRefGoogle Scholar
  19. Rinne UK, Koskinen V, Loenberg P (1980) Neurotransmitter receptors in the Parkinsonian brain. In: Rinne UK, Klinger M, Stamm G (eds) Parkinson’s disease–Current progress, problems and management. Elsevier and NorthHolland Biomedical Press, pp 93–107Google Scholar
  20. Rinne UK (1983) Dopamine agonists in the treatment of Parkinson’s disease. Adv Neurol 37: 141–150PubMedGoogle Scholar
  21. Rinne JO, Rinne JK, Laasko K, Loenberg P, Rinne UK (1985) Dopamine D-1 receptors in Parkinsonian brain. Brain Res 359: 306–310PubMedCrossRefGoogle Scholar
  22. Rinne UK (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow up. Neurology 37: 826–828PubMedGoogle Scholar
  23. Robertson GS, Robertson HA (1986) Synergistic effects of D-1 and D-2 dopamine agonists on turning behaviour in rats. Brain Res 384: 387–390PubMedCrossRefGoogle Scholar
  24. Robertson GS, Robertson HA (1987) D-1 and D-2 dopamine agonist synergism: separate sites of action. Trends Pharmacol Sci 8: 295–299CrossRefGoogle Scholar
  25. Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist European J Pharmacol 50: 419–430Google Scholar
  26. Sokoloff L, Reivich M, Kennedy C, DesRosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C] deoxyglucose method for the measurement of local cerebral glucose utilisation: theory, procedure, and normal values in the conscious and anesthetised albino rat. J Neurochem. 28: 897–916PubMedCrossRefGoogle Scholar
  27. Stern GM, Lees AJ (1983) Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson’s disease. Adv Neurol 37: 17–21PubMedGoogle Scholar
  28. Stoof JC, Kebabian JW (1981) Opossing roles for D-1 and D-2 receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366–368PubMedCrossRefGoogle Scholar
  29. Trugman JM, Wooten GF (1986) The effect of L-DOPA on regional cerebral glucose utilisation in rats with unilateral lesions of the substantia nigra. Brain Res 379: 264–274PubMedCrossRefGoogle Scholar
  30. Trugman JM, Wooten GF (1987) Selective D-1 and D-2 dopamine agonists differentially alter basal ganglia glucose utilisation in rats with unilateral 6-hydroxydopamine substantia nigra lesions. J Neurosci 7: 2927–2935PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • R. Markstein
    • 1
  • J.-M. Vigouret
    • 1
  1. 1.Preclinical ResearchSandoz Ltd.BasleSwitzerland

Personalised recommendations